A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2012
At a glance
- Drugs Tivantinib (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors ArQule
- 24 Jul 2012 Actual end date changed from 17 Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Actual end date 17 Dec 2010 added as reported by EudraCT.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by EudraCT.